Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | BCL9 | O00512 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668455 | 1.00 | MAPT (0.64) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2390983 | 0.89 | MAPT (0.55) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2390989 | 0.89 | MAPT (0.55) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29401387 | 0.89 | MAPT (0.55) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL26226843 | 0.89 | ALDH1A1 (0.67) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL22137002 | 0.89 | ALDH1A1 (0.67) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL16284648 | 0.89 | ALDH1A1 (0.67) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL22136977 | 0.88 | ALDH1A1 (0.53) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL25911506 | 0.88 | MAPT (0.53) | MAPTGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL25911512 | 0.86 | MGLL (0.52) | MAPTGAAALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | ATHIRA PHARMA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-113195641-B | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2024-09-03 | — | — | CN | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| CN-116731101-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-09-12 | — | — | CN | disclosed |
| CN-116655730-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-08-29 | — | — | CN | disclosed |
| CN-109563144-B | Compound (I) | 雅斯娜 | 2023-03-28 | — | — | CN | disclosed |
| EP-4067368-A1 | COMPOUNDS | Athira Pharma, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3464336-B1 | COMPOUNDS | ATHIRA PHARMA INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210340176-A1 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-0153277-B1 | PLEUROMUTILIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | SANDOZ AG (CH) | 1987-08-26 | — | — | EP | disclosed |
| EP-0225552-A2 | Pure enantiomeric 1,8-bridged-4-quinolo-3-carboxylic acids, process for their preparation and medicaments containing them, and their use in the preparation of medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
| EP-0117473-B1 | QUINOLONE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND ANTIBACTERIAL COMPOSITIONS CONTAINING THEM | BAYER AG (DE) | 1987-01-28 | — | — | EP | disclosed |
| EP-0206076-A2 | 1,8-Bridged 4-quinolone-3-carboxylic acids, process for their preparation as well as medicaments containing them, and their use for the preparation of medicaments | BAYER AG (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0198192-A1 | 7-Amino-1-(subst.cyclopropyl)-1,4 -dihydro-4-oxo-quinoline carboxylic acids, method for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-10-22 | — | — | EP | disclosed |
| EP-0167763-A1 | 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them | BAYER AG (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0164619-A1 | 2,4,5-Trihalo or 2,3,4,5-tetrahalo benzene derivatives and process for producing them | BAYER AG (DE) | 1985-12-18 | — | — | EP | disclosed |
| US-4559341-A | Quinolonecarboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-17 | — | — | US | disclosed |
| US-4556658-A | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
| EP-0117473-A1 | Quinolone carboxylic acids, process for their preparation and antibacterial compositions containing them | BAYER AG (DE) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340176-A1 | Compounds | BACE1, BDNF, CLN6 | MAPT 42/4885GAA 317/4885ALDH1A1 580/4885 |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | AADAT, ABAT, IAPP | MAPT 48/4885GAA 355/4885ALDH1A1 2613/4885 |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | MAPT 4365/4885GAA 134/4885ALDH1A1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.